

Exploring Psoriasis in Depth: Progress in Treatment Strategies and Disease Mechanisms

Dr. S Sharveen

Department of Pharmaceutics

School of Pharmaceutical Education and Research, Karaikal

Email: sharveens64@gmail.com

Submission Date: 25.12.2024

Accepted Date: 21.01.2025

Published Date: 31.01.2025

Copyright © 2025. The author(s). Published by *Journal of MedVerse Research and Practice*. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Abstract

Psoriasis is a long-term, autoimmune inflammatory condition that targets the skin's outer layer and has widespread effects on the body. This disorder, which impacts roughly 2–3% of people worldwide, is characterized by an imbalance in immune function and accelerated growth of skin cells. Our understanding of its pathogenesis has advanced significantly, highlighting the importance of genetic susceptibility, environmental factors, and aberrant immune mechanisms. Specifically, the interplay between Th17 cells and the IL-23/IL-17 pathway has emerged as a crucial component in this process. These advancements have enhanced both diagnostic precision and treatment approaches. While conventional therapies, including topical medications, light-based treatments, and systemic drugs such as methotrexate and cyclosporine, have provided symptom relief, their long-term effectiveness and safety profiles are limited. The introduction of biological agents targeting TNF- α , IL-17, and IL-23 pathways has revolutionized psoriasis treatment, offering improved efficacy and safety profiles. Furthermore, the development of small-molecule drugs, such as PDE4 and JAK inhibitors, has broadened therapeutic options, especially for individuals who do not tolerate or respond well to biologic treatments. Despite these improvements, challenges remain in addressing treatment-resistant cases, meeting the needs of pediatric and severe psoriasis patients, and alleviating the psychological impact of the condition. Moreover, the systemic nature of psoriasis, which is associated with additional health concerns such as cardiovascular disease, metabolic syndrome, and mental health disorders, emphasizes the importance of a holistic, interdisciplinary approach to treatment. This review summarizes findings on psoriasis pathogenesis, improvements in diagnostic methods, and evolving therapeutic strategies. It highlights the shift towards personalized treatment approaches and suggests potential directions for future investigations.

Keywords: Psoriasis, immune-mediated disease, biologics, small-molecule inhibitors, comorbidities, personalized medicine, systemic inflammation

Introduction

Psoriasis: Pathogenesis, Clinical Features, and Treatment Advances

Psoriasis is a chronic inflammatory skin disorder affecting 2–3% of the global population. It presents as erythematous, scaly plaques and is now recognized as a systemic condition linked to metabolic syndrome, cardiovascular disease, and psychological distress. The disease arises from a complex interplay of genetic predisposition, immune dysfunction, and environmental triggers [1].

Pathophysiology and Genetic Insights

Psoriasis is driven by immune system dysregulation, particularly involving the IL-23/Th17 axis. Activated T cells and dendritic cells release cytokines like IL-17, IL-23, and TNF- α , promoting keratinocyte proliferation and chronic inflammation. Genome-wide studies have identified HLA-C as a key susceptibility gene, alongside other immune-related loci. Epigenetic factors, including DNA methylation and histone modifications, further influence disease expression. Environmental triggers such as stress, infections, and lifestyle factors also contribute to disease onset and exacerbation [2].

Clinical Variants and Epidemiology

Plaque psoriasis is the most common form, but other subtypes include guttate, inverse, pustular, and erythrodermic psoriasis. The disease varies globally, with higher prevalence in Europe and North America (~2–3%) and lower rates in Asian countries (<0.5%). Psoriasis typically emerges between ages 15–35, with a secondary peak between 55–60 years [3].

Advances in Treatment

Traditional therapies include topical agents, phototherapy, and systemic drugs like methotrexate and cyclosporine. The advent of biologics targeting IL-17, IL-23, and TNF- α has revolutionized disease management, offering improved control. However, challenges such as high costs, accessibility issues, and treatment resistance remain. Newer therapies, including JAK and PDE4 inhibitors, provide alternatives for non-responders. Emerging research into the gut-skin microbiome and personalized medicine approaches may further refine treatment strategies. Despite significant advancements in psoriasis management, long-term disease control requires a comprehensive approach addressing immune mechanisms, genetic factors, and environmental influences. Ongoing research into novel therapeutic targets, early diagnosis, and individualized treatment strategies will be essential in improving patient outcomes [4].

Role of Environmental Triggers and Microbiome

Psoriasis is a multifactorial disease in which environmental stimuli modulate genetic susceptibility, thereby contributing to the onset and exacerbation of the condition. Psoriasis is known to be influenced by a variety of environmental factors, such as stress, infections, and lifestyle choices.

Triggers of Environmental

Stress is a recognized trigger for psoriasis exacerbations, perhaps because to its impact on immunological dysregulation. The hypothalamic-pituitary-adrenal (HPA) axis is stimulated by psychological stress, leading to the secretion of cortisol. This hormone may affect immunological responses and stimulate inflammation. Guttate psoriasis is linked to infections, especially streptococcal pharyngeal infections. Psoriasis lesions may be triggered or aggravated by several circumstances, including tobacco use, excessive alcohol intake, skin damage (Köbner phenomenon), and certain pharmaceuticals [5].

Influence of the Microbiome

The human microbiome's intestinal and skin microbiota play a crucial role in controlling inflammation and immunological responses in psoriasis. Research has shown that psoriasis patients have modified skin microbiomes, characterized by an increase in pro-inflammatory bacteria, such as *Staphylococcus aureus*, and a decrease in variety. Microbial imbalances may intensify cutaneous inflammation by stimulating immunological responses via pattern recognition receptors (PRRs). Systemic inflammation has also been connected to gut microbiome dysbiosis, which further affects psoriasis severity. The therapeutic advantages of re-establishing a healthy microbiome by topical therapies, probiotics, or dietary

modifications may aid in the management of psoriasis. Formulating tailored strategies for the prevention and management of psoriasis requires comprehension of the interaction between environmental variables and the microbiome [6].

Diagnostic Approaches in Psoriasis




Figure 1: Overview of diagnostic approaches for psoriasis, including histological analysis, dermoscopy, clinical evaluation, advanced imaging, and emerging biomarkers.

Clinical evaluation, including patient history and physical exam, is the primary method for diagnosing psoriasis. The diagnosis relies on characteristic features, such as reddened lesions with silvery scales, typically on the scalp, elbows, and knees. In rare or ambiguous cases, histological analysis can be beneficial. Psoriasis is often confirmed through skin biopsy findings of hyperkeratosis, acanthosis, and elongated rete ridges. Recent advancements have focused on dermoscopy, a non-invasive approach [7].

Clinical Presentation and Subtypes

Psoriasis is characterized by erythematous plaques covered with silvery-white scales, commonly affecting the scalp, elbows, and knees. Patients may experience itching, burning, or pain. Nail involvement, such as subungual hyperkeratosis, onycholysis, and discoloration, is also frequent. Additionally, psoriatic arthritis may develop, leading to joint complications.

Psoriasis presents in several subtypes:

- **Plaque Psoriasis:** The most prevalent form, featuring well-defined, raised, scaly plaques, usually on the scalp, elbows, and knees.
- **Guttate Psoriasis:** Small, drop-like lesions often triggered by infections, particularly streptococcal throat infections.
- **Pustular Psoriasis:** Characterized by white pustules surrounded by inflamed skin, which may be localized or widespread.
- **Inverse Psoriasis:** Smooth, erythematous lesions found in skin folds, such as the axillae and groin, lacking the typical scaling.
- **Erythrodermic Psoriasis:** A rare but severe form causing widespread redness, scaling, and systemic complications.

Biomarkers and Diagnostic Advances

Recent research has identified key biomarkers such as IL-17, IL-23, TNF- α , and CRP, which aid in disease assessment and therapeutic monitoring. Advanced imaging techniques, including confocal laser scanning microscopy and optical coherence tomography (OCT), enable detailed visualization of psoriatic lesions. Serum biomarkers, such as S100 proteins, provide insights into disease activity, while genetic markers like HLA-C improve classification and facilitate personalized treatment approaches [8].

Imaging Techniques in Psoriasis

Modern imaging tools enhance diagnostic precision and treatment monitoring:

- **High-Resolution Ultrasound (HRUS):** Evaluates skin thickness, vascularity, and subclinical inflammation.
 - **Confocal Laser Scanning Microscopy (CLSM):** Offers high-resolution imaging of epidermal and dermal layers, useful for assessing inflammation and therapeutic response.
 - **Magnetic Resonance Imaging (MRI):** Primarily used for psoriatic arthritis, allowing visualization of joint inflammation.
 - **Optical Coherence Tomography (OCT):** Provides real-time, detailed imaging of epidermal changes, aiding in disease assessment and treatment monitoring.
- Current Therapeutic Approaches, Psoriasis management focuses on symptom control, inflammation reduction, and quality-of-life improvement.
- **Topical Treatments:** First-line options for mild to moderate cases include corticosteroids, vitamin D analogy, and calcineurin inhibitors.
 - **Phototherapy:** Narrowband UVB and PUVA are effective for moderate to severe cases by regulating excessive keratinocyte proliferation.
 - **Systemic Therapies:** Methotrexate, cyclosporine, and acitretin are commonly used for severe disease but require careful monitoring due to potential side effects.
 - **Biologic Agents:** Targeted therapies blocking TNF- α , IL-17, and IL-23 have revolutionized treatment, offered significant symptom relief but required long-term administration.
 - **Janus Kinase (JAK) Inhibitors:** Emerging oral therapies providing a promising alternative to biologics with more convenient dosing regimens. These advancements highlight the importance of personalized approaches in optimizing psoriasis management.




Figure 2: Overview of psoriasis treatments, including topical medications, phototherapy, systemic treatments, and biologics [9].

Conventional and Emerging Psoriasis Treatments

Traditional Therapies

Psoriasis treatment primarily involves topical therapies and phototherapy. Corticosteroids remain the most widely used, reducing inflammation and scaling. Vitamin D analogs, such as calcipotriene, regulate epidermal cell growth, while coal tar and retinoids like tazarotene aid in normalizing skin turnover. For moderate to severe cases, phototherapy, particularly narrowband UVB, is the preferred option due to its efficacy and lower risk profile. PUVA therapy, though effective, has limitations due to potential long-term skin damage [10].

Systemic and Biologic Therapies

Systemic treatments, including methotrexate, cyclosporine, and acitretin, help manage severe psoriasis by modulating immune responses or slowing excessive cell proliferation. However, these drugs require monitoring due to potential adverse effects, such as liver and kidney toxicity. Biologic agents have transformed treatment, offering targeted inhibition of inflammatory pathways. TNF- α blockers (adalimumab, etanercept) and newer IL-17 and IL-23 inhibitors (secukinumab, guselkumab) provide sustained remission with fewer side effects [11].

Small Molecule Inhibitors

Targeted oral therapies, such as Janus kinase (JAK) inhibitors (tofacitinib, baricitinib) and phosphodiesterase 4 (PDE4) inhibitors (apremilast), are emerging as viable alternatives. JAK inhibitors reduce inflammatory cytokine activity, while PDE4 inhibitors regulate immune responses, offering symptom relief with convenient oral administration.

Future Directions and Challenges

Innovations in psoriasis management focus on gene therapy, precision medicine, and advanced biologics. CRISPR-based interventions and autologous T-cell therapies show promise for long-term control. However, treatment accessibility, high biologic costs, and disease heterogeneity remain key challenges. Integrating personalized medicine through biomarker-driven therapies may enhance outcomes. [12]

Addressing Comorbidities

Psoriasis is linked to systemic conditions, including cardiovascular disease, metabolic syndrome, and mental health disorders. Psoriatic arthritis affects nearly one-third of patients, necessitating a multidisciplinary approach. Early intervention, lifestyle modifications, and comprehensive care strategies are crucial for managing both skin symptoms and associated health risks.

Long-Term Safety, Treatment Resistance, and Future Outlook

Safety Concerns and Access to Care

The long-term safety of biologics remains a concern, given potential risks like immunosuppression, malignancy, and cardiovascular effects. While IL-17 and IL-23 inhibitors have expanded treatment options, real-world data on prolonged use is still emerging. Additionally, affordability remains a significant barrier, particularly in lower-income regions. Reducing treatment costs, improving insurance coverage, and strengthening healthcare systems are crucial for broader access [13].

Challenges in Treatment Response

Despite advancements, some patients do not respond to biologics due to genetic factors, immune adaptations, or the development of neutralizing antibodies. Comorbid conditions and inconsistent adherence can further impact treatment efficacy. Addressing resistance requires precision medicine approaches, optimizing therapies based on individual genetic and immunological profiles [14].

Summary

Psoriasis is a chronic, immune-mediated inflammatory skin disorder affecting 2 to 3 percent of the global population and is increasingly recognized as a systemic disease associated with metabolic, cardiovascular, and psychological comorbidities. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, particularly the IL-23/Th17 axis, and environmental triggers such as stress, infections, and lifestyle factors. Genetic susceptibility is influenced by loci like HLA-C and epigenetic modifications, while microbial imbalances in the skin and gut may exacerbate inflammation. Clinically, psoriasis manifests in multiple forms including plaque, guttate, pustular, inverse, and erythrodermic subtypes, often affecting the scalp, elbows, knees, and skin folds. Nail involvement and psoriatic arthritis are common, adding to disease burden. Diagnosis relies on clinical evaluation, histology, dermoscopy, and advanced imaging, supported by biomarkers such as IL-17, IL-23, TNF-alpha, CRP, S100 proteins, and genetic markers. Management ranges from topical therapies and phototherapy for mild disease to systemic agents and biologics for moderate to severe cases. Biologics targeting TNF-alpha, IL-17, and IL-23 have transformed treatment, while emerging oral inhibitors including JAK and PDE4 inhibitors provide additional options. Challenges include treatment resistance, long-term safety concerns, high costs, and limited accessibility. Comprehensive care requires addressing comorbidities, promoting adherence, and integrating multidisciplinary approaches. Ongoing research into novel therapeutic targets, biomarkers, and individualized strategies is essential to improve outcomes and ensure long-term disease control.

Conclusion

Psoriasis is a complex immune-mediated disorder with significant therapeutic progress in recent years. Targeted biologics have revolutionized management, yet challenges remain in treatment resistance, accessibility, and long-term safety. Future research should focus on novel therapies, early intervention, and personalized medicine to enhance disease control and improve patient outcomes.

References

1. Ahamad, N., Kar, A., Mehta, S., Dewani, M., Ravichandran, V., Bhardwaj, P., Sharma, S., Banerjee, R., 2021. Immunomodulatory nanosystems for treating inflammatory diseases. *Biomaterials*. <https://doi.org/10.1016/j.biomaterials.2021.120875>
2. Armstrong, A.W., Bohannon, B., Mburu, S., Coates, L.C., Ogdie, A., Alarcon, I., Kasparek, T., Frade, S., Barrio, S.F., Augustin, M., 2023. Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey. *Dermatology*. <https://doi.org/10.1159/000528945>
3. Attri, D.S., Rathour, A., Ray, R.K., Kumar, V., 2023. Formulation and evaluation of hydrogel for topical drug delivery of Zingiber officinale Rosc . and Withania somnifera (L .) Dunal to increase the bioavailability of oils for the treatment of arthritis 12, 1–10.
4. Bakewell, C., Aydin, S.Z., Ranganath, V.K., Eder, L., Kaeley, G.S., 2020. Imaging Techniques:Options for the Diagnosis and Monitoring of Treatment of Enthesitis in Psoriatic Arthritis. *Journal of Rheumatology*. <https://doi.org/10.3899/jrheum.190512>

5. Bakshi, H., Nagpal, M., Singh, M., Dhingra, G.A., Aggarwal, G., 2020. Treatment of Psoriasis: A Comprehensive Review of Entire Therapies. Current Drug Safety. <https://doi.org/10.2174/1574886315666200128095958>
6. Balan, R., Grigoras, A., Popovici, D., Amalinei, C., 2019. The histopathological landscape of the major psoriasiform dermatoses. *Archive of Clinical Cases*. <https://doi.org/10.22551/2019.24.0603.10155>
7. Bhagwat, A.P., Madke, B., 2023. The Current Advancement in Psoriasis. *Cureus*. <https://doi.org/10.7759/cureus.47006> Burger, B., Sagiorato, R.N., Cavenaghi, I., Rodrigues, H.G., 2023. Abnormalities of Sphingolipids Metabolic Pathways in the Pathogenesis of Psoriasis. *Metabolites*. <https://doi.org/10.3390/metabo13020291>
8. Campanati, A., Diotallevi, F., Martina, E., Radi, G., Offidani, A., 2022. Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities. *Journal of Clinical Medicine*. <https://doi.org/10.3390/jcm11092422>
9. Campbell, K., Li, K., Yang, F., Branigan, P., Elloso, M.M., Benson, J., Orlovsky, Y., Chen, Y., Garcet, S., Krueger, J.G., 2023. Guselkumab More Effectively Neutralizes PsoriasisAssociated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab. *ImmunoHorizons*. <https://doi.org/10.4049/immunohorizons.2300003>
10. Canal-García, E., Bosch-Amate, X., Belinchón, I., Puig, L., 2022. Nail Psoriasis. *Actas DermoSifiliograficas*. <https://doi.org/10.1016/j.ad.2022.01.006>
11. Celoria, V., Rosset, F., Pala, V., Dapavo, P., Ribero, S., Quaglino, P., Mastorino, L., 2023. The Skin Microbiome and Its Role in Psoriasis: A Review. *Psoriasis: Targets and Therapy*. <https://doi.org/10.2147/ptt.s328439>
12. Chen, C., Che, K., Guo, Y., Huang, Q., Hu, X., Yu, B., 2023. Effect of the age of onset on epidemiology, clinical features, and comorbidity of geriatric psoriasis. *The Journal of Dermatology* 50, 1156–1161. <https://doi.org/10.1111/1346-8138.16856>
13. Chen, T., Zhu, S.J., Xu, S., Wang, Y.Q., Aji, A., Zhang, C., Wang, H., Li, F.L., Chu, Y.X., 2023. Resting-state fMRI reveals changes within the anxiety and social avoidance circuitry of the brain in mice with psoriasis-like skin lesions. *Experimental Dermatology*. <https://doi.org/10.1111/exd.14914>
14. Damiani, G., Conic, R.R.Z., Pigatto, P.D.M., Carrera, C.G., Franchi, C., Cattaneo, A., Malagoli, P., Uppala, R., Linder, D., Bragazzi, N.L., Grossi, E., 2020. Predicting Secukinumab Fast Responder Profile in Psoriatic Patients: Advanced Application of Artificial-Neural Networks (ANNs). *Journal of Drugs in Dermatology*. <https://doi.org/10.36849/JDD.2020.5006>